Boehringer In­gel­heim boosts R&D com­mit­ment, promis­es up to 15 new prod­uct launch­es by 2025

Com­ing off a strong year of growth for its Eli Lil­ly-part­nered SGLT2 in­hibitor Jar­diance, Boehringer In­gel­heim is putting those gains right back in­to R&D …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.